Baird believes the positive results from the long-term study analyses of vatiquinone in Friedreich ataxia, in combination with the regulatory alignment with the FDA on the NDA submission, will have positive implications for PTC Therapeutics’ stock, the analyst tells investors in a research note. The firm thinks it is very likely that the filing, which is expected to be submitted in December, will be at least accepted by the FDA for review, saying the magnitude of benefit from the two comparisons with natural history appear very strong. The firm made no change to its Outperform rating or $44 price target
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTCT:
- PTC Therapeutics provides update on vatiquinone Friedreich ataxia program
- PTC Therapeutics announces FDA acceptance for filing of NDA for sepiapterin
- PTC Therapeutics’ fast track designation for PTC518 ‘positive,’ says Baird
- PTC Therapeutics: FDA grants Fast Track designation to the PTC518 program
- PTC Therapeutics selloff ‘not warranted,’ says Morgan Stanley
Questions or Comments about the article? Write to editor@tipranks.com